ARS Pharmaceuticals, Inc.
Clinical trials sponsored by ARS Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing treatments for severe allergic reactions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Nasal spray vs. needle: new study tests easier allergy rescue Results expected Apr 2027 (estimated)
- New hives drug shows promise in early trial Results expected Jun 2027 (estimated)
-
New hives drug shows promise in early trial
Symptom relief Recruiting nowThis study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…
Phase 2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Nasal spray vs. needle: new study tests easier allergy rescue
Symptom relief Recruiting nowThis study looks at the safety of a nasal spray called neffy compared to a standard epinephrine shot for treating allergic reactions. It involves 600 people aged 4 and older who have an allergic reaction during a food challenge or allergy shot session. The goal is to see if the s…
Phase 4 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC